CTLA4 and neoplasm: CTLA-4, which is downregulated in the low-immune group, is the first negative regulator of T cell activation identified in the context of antitumor immunity, and its blockade using monoclonal antibodies triggers tumor regression with durable antitumor immunity in preclinical models.